As of November 7, 2026, BIO-TECHNE Corp is a publicly traded company (Nasdaq: TECH); its largest reported holder is Vanguard, with 7.38% on Schedule 13G of April 29, 2026, then BlackRock (7%). The largest insider holding is James Hippel, the chief financial officer, with 176,720 shares (0.11% of shares outstanding), per Form 4 of November 3, 2026 (Schedule 13G, April 29, 2026).
Is this your company?
About to sign with, pay or invest in BIO-TECHNE Corp? See the free Snapshot first.
Free to see. No signup.
Is BIO-TECHNE Corp a real, registered company?
- BIO-TECHNE Corp files with the SEC under CIK 842023 (its SEC filings).
- Its shares are listed under the ticker TECH on Nasdaq (SEC company record).
- Incorporated in Minnesota; business address in Minneapolis, Minnesota, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under BIO-TECHNE CORP in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-08-06).
Who are BIO-TECHNE Corp's owners and officers?
BIO-TECHNE Corp: incorporated in Minnesota; business address in Minneapolis, Minnesota; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 0.7% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 8.1% |
| Schedule 13G, 2026-05-06 | Fmr LLC | 5% |
| Schedule 13G, 2026-04-29 | Vanguard Capital Management | 7.38% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2025-11-14 | T. Rowe Price Associates, Inc. | 2.2% |
| Schedule 13G/A, 2025-08-14 | T. Rowe Price Associates, Inc. | 5.6% |
| Schedule 13G/A, 2025-07-16 | Blackrock, Inc. | 7% |
Questions about who owns BIO-TECHNE Corp
Who owns BIO-TECHNE Corp?
On this page, 2 holders' latest ownership filings report 5% or more of BIO-TECHNE Corp: Vanguard Capital Management (7.38%, Schedule 13G, filed 2026-04-29) and Blackrock, Inc. (7%, Schedule 13G/A, filed 2025-07-16).
Who are the largest shareholders of BIO-TECHNE Corp?
By the share each holder's latest filing reports, the largest holders of BIO-TECHNE Corp on this page are Vanguard Capital Management (7.38%) and Blackrock, Inc. (7%).
When did Vanguard Capital Management buy into BIO-TECHNE Corp?
The filings give report dates, not purchase dates. The earliest filing from Vanguard Capital Management on this page is the Schedule 13G, filed 2026-04-29, reporting 7.38%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on BIO-TECHNE Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BIO-TECHNE Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BIO-TECHNE Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own BIO-TECHNE Corp shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief financial officer: 176,720 shares (0.11% of shares outstanding) (Form 4, 2026-11-03).
- , the chief executive and a director: 80,509 shares (0.05% of shares outstanding) (Form 4, 2026-11-03).
- , a director: 80,004 shares (0.05% of shares outstanding) (Form 4, 2026-11-02).
- , a director: 59,634 shares (0.04% of shares outstanding) (Form 4, 2026-11-02).
- , a director: 44,559 shares (0.03% of shares outstanding) (Form 4, 2025-08-27).
Shares outstanding: 157,090,727 as of 2026-11-02, from the company's latest SEC cover page.
How much has BIO-TECHNE Corp raised?
No fundraising or offering filing from BIO-TECHNE Corp is on file with us.
Keep reading
More on BIO-TECHNE Corp and the records around it.
Companies that share a holder
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: PACIFIC BIOSCIENCES OF CALIF (Nov 2026), APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/bio-techne